Figure 4.
Overall survival (OS) by first taxane or PARP inhibitor therapy, in (A) patients with ATM mutations and (B) patients with BRCA2 mutations.PARP, poly(ADP‐ribose) polymerase. [Color figure can be viewed at wileyonlinelibrary.com]
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.